All In Biotech

Drug Trial Radar · NCT06523088

A Study of PN20 in Healthy Adult Volunteers

A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of PN20 in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Jun 16, 2022

Primary completion

Jan 5, 2023

Study completion Jan 5, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main aim of this clinical trial is to assess the safety of PN20 in healthy volunteers aged 18 to 50 years. The main questions it aims to answer are: * Is PN20 safe in adult? Researchers will compare PN20 to a placebo (a look-alike substance that contains no drug) to see if PN20 is safe. Participants will * Receive a single dose injection of PN20 or placebo according to weight, * Stay in hospital for assessment.

Conditions

  • Chemotherapy-induced Thrombocytopenia
  • Immune Thrombocytopenic Purpura

Interventions

  • PN20Drug

    Six dose levels of PN20 will be evaluated

  • PlaceboDrug

    Placebo of PN20

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-related Adverse EventsTime frame: up to 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangshu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.